# Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

> **NCT00290901** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 754 (—)

## Conditions studied

- Back Pain

## Interventions

- **DRUG:** Tramadol Hydrochloride 50mg
- **DRUG:** Celebrex 200mg

## Key facts

- **NCT ID:** NCT00290901
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-12
- **Final completion:** —
- **Target enrollment:** 754 (—)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290901, "Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00290901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*